ATE435026T1 - Verfahren zur prävention und behandlung von diabetes mit neurturin - Google Patents

Verfahren zur prävention und behandlung von diabetes mit neurturin

Info

Publication number
ATE435026T1
ATE435026T1 AT04803341T AT04803341T ATE435026T1 AT E435026 T1 ATE435026 T1 AT E435026T1 AT 04803341 T AT04803341 T AT 04803341T AT 04803341 T AT04803341 T AT 04803341T AT E435026 T1 ATE435026 T1 AT E435026T1
Authority
AT
Austria
Prior art keywords
diabetes
neurturin
prevention
treatment
administering
Prior art date
Application number
AT04803341T
Other languages
English (en)
Inventor
Matthias Austen
Ulrike Burk
Original Assignee
Develogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen Ag filed Critical Develogen Ag
Application granted granted Critical
Publication of ATE435026T1 publication Critical patent/ATE435026T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
AT04803341T 2003-11-27 2004-11-29 Verfahren zur prävention und behandlung von diabetes mit neurturin ATE435026T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03027383 2003-11-27
PCT/EP2004/013534 WO2005051415A1 (en) 2003-11-27 2004-11-29 Method for preventing and treating diabetes using neurturin

Publications (1)

Publication Number Publication Date
ATE435026T1 true ATE435026T1 (de) 2009-07-15

Family

ID=34626383

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04803341T ATE435026T1 (de) 2003-11-27 2004-11-29 Verfahren zur prävention und behandlung von diabetes mit neurturin

Country Status (9)

Country Link
US (4) US20080241106A1 (de)
EP (1) EP1694354B1 (de)
JP (5) JP4838724B2 (de)
AT (1) ATE435026T1 (de)
DE (1) DE602004021847D1 (de)
DK (1) DK1694354T3 (de)
ES (1) ES2329583T3 (de)
PL (1) PL1694354T3 (de)
WO (1) WO2005051415A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
PL1694354T3 (pl) 2003-11-27 2009-12-31 Develogen Ag Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
EP1872790A1 (de) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft Neue Zusammensetzung zur Erhöhung der Bioverfügbarkeit von Neurturin
US8637459B2 (en) * 2006-11-08 2014-01-28 Emory University Enhancing a population of insulin releasing cells using GFR-A1 agonists
JP2011503019A (ja) * 2007-11-05 2011-01-27 デベローゲン アクティーゲンゲゼルゲゼルシャフト 薬学的使用のための新規のニュールツリン複合体
JP2011057674A (ja) 2009-09-11 2011-03-24 Omnica Gmbh コエンザイムｑ−１０と抗酸化剤とを含む組成物
US9127083B2 (en) 2009-10-30 2015-09-08 Ntf Therapeutics, Inc. Neurturin molecules
BR112012009801A8 (pt) * 2009-10-30 2016-08-30 Cns Therapeutics Inc Polipeptídeo neurturina e variante de neurturina
US8445432B2 (en) 2009-10-30 2013-05-21 Ntf Therapeutics Inc Neurturin molecules
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9617517B2 (en) 2011-05-02 2017-04-11 National University Corporation Kumamoto University Small chemical compound which promotes induction of differentiation of stem cells into insulin-producing cells and method for inducing differentiation of stem cells into insulin-producing cells using said small chemical compound
WO2013063389A2 (en) * 2011-10-26 2013-05-02 University Of Louisville Research Foundation, Inc. Methods and compositions for treating diabetes and other degenerative neuroendocrine diseases or disorders
US9821026B2 (en) * 2012-06-28 2017-11-21 Instituto De Medicina Molecular Use of RET agonist molecules for haematopoietic stem cell expansion protocols and transplantation therapy and a RET agonist kit
CN105358678A (zh) * 2013-03-08 2016-02-24 密苏里大学董事会 治疗和/或预防1型糖尿病的方法和组合物
KR20170086659A (ko) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用
JP6960106B2 (ja) * 2018-01-17 2021-11-05 Toto株式会社 浴槽用枕
CN114401740A (zh) * 2019-05-30 2022-04-26 伊美诺路克斯国际公司 痘病毒与自体诱导性多能干细胞用于疫苗接种和疾病治疗的用途
EP4284440A1 (de) * 2021-01-30 2023-12-06 Universitat Autònoma De Barcelona Gentherapie für monogene diabetes
CN115245556A (zh) * 2021-04-27 2022-10-28 复旦大学附属华山医院 蛋白酶体抑制剂伊沙佐米在制备治疗糖尿病药物中的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6743628B1 (en) 1995-08-28 2004-06-01 Washington University Method of cell culture using neurturin
AU718500B2 (en) 1997-01-23 2000-04-13 Sumitomo Pharmaceuticals Company, Limited Remedies for diabetes
AU730430B2 (en) * 1997-02-18 2001-03-08 Genentech Inc. Neurturin receptor
US6043221A (en) 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
AU778998B2 (en) 1998-09-22 2004-12-23 University Of Maryland At Baltimore Cystine knot growth factor mutants
WO2000018922A2 (en) 1998-10-01 2000-04-06 Incyte Genomics, Inc. Human carbohydrate-associated proteins
PT1223966E (pt) 1999-10-29 2003-09-30 Biopharm Ges Biotechn Entwickl Utilizacao do gdnf para tratamento de defeitos na cornea
AU2001233114A1 (en) 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
EP1379626A2 (de) * 2001-04-19 2004-01-14 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Verfahren zur differenzierung von stammzellen in insulin-produzierenden zellen
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
JP2005527614A (ja) 2002-05-29 2005-09-15 デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング 膵臓特異性タンパク質
WO2004093804A2 (en) 2003-04-18 2004-11-04 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
PL1694354T3 (pl) * 2003-11-27 2009-12-31 Develogen Ag Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
EP1872790A1 (de) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft Neue Zusammensetzung zur Erhöhung der Bioverfügbarkeit von Neurturin
JP2011503019A (ja) 2007-11-05 2011-01-27 デベローゲン アクティーゲンゲゼルゲゼルシャフト 薬学的使用のための新規のニュールツリン複合体

Also Published As

Publication number Publication date
JP2014074066A (ja) 2014-04-24
DK1694354T3 (da) 2009-10-26
WO2005051415A1 (en) 2005-06-09
US8772233B2 (en) 2014-07-08
JP5647577B2 (ja) 2015-01-07
JP2007512290A (ja) 2007-05-17
US20080241106A1 (en) 2008-10-02
JP2011251986A (ja) 2011-12-15
DE602004021847D1 (de) 2009-08-13
JP2016000759A (ja) 2016-01-07
PL1694354T3 (pl) 2009-12-31
JP4838724B2 (ja) 2011-12-14
US20130150293A1 (en) 2013-06-13
US8399408B2 (en) 2013-03-19
JP2012001546A (ja) 2012-01-05
US20110256113A1 (en) 2011-10-20
US20140274897A1 (en) 2014-09-18
EP1694354B1 (de) 2009-07-01
ES2329583T3 (es) 2009-11-27
EP1694354A1 (de) 2006-08-30

Similar Documents

Publication Publication Date Title
ATE435026T1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE480255T1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
DE60223058D1 (de) Zusammensetzungen und verfahren zur behandlung von diabetes
ATE331527T1 (de) Verfahren zur behandlung von brustdrüsenerkrankungen
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
WO2006001877A3 (en) Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
EA200702212A1 (ru) Способ лечения или профилактики разрушения кости или остеопороза
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
ATE411803T1 (de) Verfahren zur behandlung von schwerer herzinsuffizienz und medikament dafür
DE602004002394D1 (de) (3-ä3-'(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINOÜ-PROPOXYü-PHENYL)-ESSIGSÄURE UND VERWANDTE VERBINDUNGEN ALS MODULATOREN VON PPARS UND VERFAHREN ZUR BEHANDLUNG VON STOFFWECHSELSTÖRUNGEN
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
ATE423110T1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE397924T1 (de) Satraplatin zur behandlung von resistenten oder refrkatären tumoren
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
DE602004024871D1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
DE60318081D1 (de) Verwendung von brimonidine zur behandlung von dementia und morbus parkinson
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
DE502004011486D1 (de) Antioxidationsmittel für organisches material und verfahren zur behandlung desselben

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1694354

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1694354

Country of ref document: EP